Trial · NCT06267664
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain freedom at 2 hours | Two hours after treatment intake | The percentage of subjects who become pain free at two hours after treatment, before the use of any rescue medication |
| Primary | Absence of the most bothersome symptom | Two hours after treatment intake | Absence of the most bothersome migraine-asso- ciated symptom at 2 hours after treatment |
| Secondary | Pain freedom at 8 hours | Eight hours after treatment intake | The percentage of subjects who become pain free at eight hours after treatment, before the use of any rescue medication |
| Secondary | Pain freedom at 24 hours | 24 hours after treatment intake | The percentage of subjects who become pain free at 24 hours after treatment, before the use of any rescue medication |
| Secondary | Sustained pain freedom | Twenty-four hours after treatment intake | percentage of subjects who are pain free at 2 hours with no use of rescue medication or relapse within 24 hours of the initial treatment. |
| Secondary | Total freedom from migraine at 2 hours | Two hours after treatment intake | Percentage of subjects who report Freedom from headache and any migraine- associated symptoms at two hours |
| Secondary | Total freedom from migraine at 8 hours | Eight hours after treatment intake | Percentage of subjects who report Freedom from headache and any migraine- associated symptoms at eight hours |
| Secondary | Total freedom from migraine at 24 hours | Twenty-four hours after treatment intake | Percentage of subjects who report Freedom from headache and any migraine- associated symptoms at 24 hours |
| Secondary | Headache relief at 2 hours | Two hours after treatment intake | Percentage of subjects who report decrease in headache pain from moderate or severe at baseline to mild or none at 2 hours after treatment and before taking any rescue medication |
| Secondary | Headache relief at 8 hours | Eight hours after treatment intake | Percentage of subjects who report decrease in headache pain from moderate or severe at baseline to mild or none at 2 hours after treatment and before taking any rescue medication |
| Secondary | Headache relief at 24 hours | 24 hours after treatment intake | Percentage of subjects who report decrease in headache pain from moderate or severe at baseline to mild or none at 2 hours after treatment and before taking any rescue medication |
| Secondary | Time to meaningful relief | 24 hours after treatment intake | Number of minutes between the acute drug intake and the presence of meaningful relief |
| Secondary | Time to pain freedom | 24 hours after treatment intake | Number of minutes between the acute drug intake and the presence of pain freedom |
| Secondary | Time to migraine freedom | 24 hours after treatment intake | Number of minutes between the acute drug intake and the presence of migraine freedom |
| Secondary | Need of rescue medication at 2 hours | 2 hours after treatment intake | The percentage of patients taking rescue medication 2 hours after intake of the drug |
| Secondary | Need of rescue medication at 8 hours | 8 hours after treatment intake | The percentage of patients taking rescue medication 8 hours after intake of the drug |
| Secondary | Need of rescue medication at 24 hours | 24 hours after treatment intake | The percentage of patients taking rescue medication 24 hours after intake of the drug |
| Secondary | Tolerability of the drugs | 24 hours after the treatment intake | To describe the frequency and type of adverse events |
| Secondary | Response predictors at 2 hours | Assessed at 2 hours after the acute drug use. | To evaluate which demographic and clinical variables are associated with a higher probability of response at 2 hours |
| Secondary | Response predictors at 24 hours | Assessed at 24 hours after the acute drug use. | To evaluate which demographic and clinical variables are associated with a higher probability of response at 24 hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06267664/registered